Kiran Mazumdar-Shaw

“As a traditionally risk-averse nation, India has rarely been at the forefront of innovation. Indian companies have mostly imitated others and became very good at it.”

“Once you start succeeding, you start dreaming big. For me, it was that way.”

“I want to make sure that our bio-similars capture a huge market share and help cancer patients around the world, which we are already doing in the developing world because we didn't have access to these drugs. Biocon enjoys a large reputation of giving them high-quality cancer drug.”

“Innovation and commerce are as powerful tools for creating social progress as they are for driving technological advancement.”

“It was a chance encounter with a biotech entrepreneur from Ireland that got me started as an entrepreneur in India, because I partnered this Irish company in setting up India's first biotech company.”

“Biocon is on a journey of making impact on global healthcare. I have to make sure that I have one in five persons who needs insulin therapy to use a Biocon product - that is my dream.”

“It is always nice to reflect on how one started.”

“Unfortunately, our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very, very strong balance sheet with huge value drivers at the end of it.”